(Q36290926)

English

Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

Europe PubMed Central

Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

1

object named as

Maria Buti

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

author name string

Miguel A Casado

2

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Leslie Fosbrook

3

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Rafael Esteban

4

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1043-1055

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular diagnosis of viral hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmaceutical Expenditure and Therapeutic Value of New Medicines in Spain

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring of viral levels during therapy of hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NICE methodological guidelines and decision making in the National Health Service in England and Wales

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European healthcare policies for controlling drug expenditure

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using economic evaluations to make formulary coverage decisions. So much for guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fundholding: learning from the past and looking to the future.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring Response to Antiviral Therapy for Patients with Chronic Hepatitis C Virus Infection by a Core-Antigen Assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

1 reference

https://pubmed.ncbi.nlm.nih.gov/16235977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200523100-00007

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36290926&oldid=2198565901"